Your browser doesn't support javascript.
loading
Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral Blood.
Samoila, Aliaksandra; Sosa, Jose; Padilla, Jessica; Wutkowski, Michael; Vanness, Katelynd; Viale, Agnes; Berger, Michael; Houck-Loomis, Brian; Pessin, Melissa; Peerschke, Ellinor I.
Afiliação
  • Samoila A; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Sosa J; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Padilla J; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Wutkowski M; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Vanness K; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Viale A; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Berger M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Houck-Loomis B; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Pessin M; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Peerschke EI; Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
J Appl Lab Med ; 5(4): 788-797, 2020 07 01.
Article em En | MEDLINE | ID: mdl-32603443
ABSTRACT

BACKGROUND:

Cell-free DNA (cfDNA) analysis using peripheral blood represents an exciting, minimally invasive technology for cancer diagnosis and monitoring. The reliability of testing is dependent on the accuracy and sensitivity of specific molecular analyses to detect tumor-associated genomic variants and on the quantity and quality of cfDNA available for testing. Specific guidelines for standardization and design of appropriate quality programs focused specifically on cfDNA isolation are lacking, as are standardized quality control reagents. CONTENT This report describes and illustrates quality control and quality assurance processes, supported by generation of in-house quality control material, to ensure the reliability of the preanalytical phase of cfDNA analysis.

SUMMARY:

We have developed a robust quality program to support high-volume automated cfDNA extraction from peripheral blood by implementing processes and procedures designed to monitor the adequacy of specimen collection, specimen stability, efficiency of cfDNA extraction, and cfDNA quality.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coleta de Amostras Sanguíneas / Guias como Assunto / Serviços de Laboratório Clínico / DNA Tumoral Circulante / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coleta de Amostras Sanguíneas / Guias como Assunto / Serviços de Laboratório Clínico / DNA Tumoral Circulante / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article